Acute Kidney Injury, Covid19, Inflammation, Outcome, Fatal, Respiratory Failure
Conditions
Keywords
SuPAR, CRP, D-dimer, Ferritin, Interleukin-6, Procalcitonin, lactate dehydrogenase, biomarkers
Brief summary
This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.
Detailed description
All consecutive patients hospitalized specifically for Covid-19 at the University of Michigan in Ann Arbor from February 1st, 2020 to date are included. Other participating centers will enroll patients depending on their variable capacity. Patients with a positive test for SARS-CoV-2 but hospitalized for non-Covid-19 reasons were excluded. Blood-based biomarkers including soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6 are measured in samples collected within 48 hours of presentation. The primary outcome of the study is the composite endpoint of in-hospital mortality, need for mechanical ventilation and need for renal replacement therapy.
Interventions
DIAGNOSTIC_TESTSuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Biomarkers of inflammation
Sponsors
Rush University
Copenhagen University Hospital, Hvidovre
University of Athens
Heinrich-Heine University, Duesseldorf
University of Thessaly
Charite University, Berlin, Germany
University of Michigan
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Positive SARS-CoV-2 test result * Covid-19 as the primary reason for hospitalization
Exclusion criteria
* Hospitalized primarily for non-Covid-19 reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In-hospital incidence of death, need for mechanical ventilation and need for renal replacement therapy | during COVID91 related hospitalization, up to 6 months | Composite outcome of death, need for mechanical ventilation, need for renal replacement therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Kidney Injury | within 6 months | Per KDIGO criteria |
| Cardiovascular Events | within 6 months | In-hospital new diagnosis heart failure, arrhythmia, myocardial infarction |
| Length of Hospitalization | up to 6 months | Duration of hospitalization |
| Need for renal replacement therapy | within 6 months | In-hospital renal replacement therapy or dialysis |
| Need for mechanical ventilation | within 6 months | Respiratory failure requiring mechanical ventilation |
| Death | within 6 months | In-hospital mortality |
Countries
United States
Outcome results
None listed